$PIRS
Pieris Pharmaceuticals Inc

2018 Q1 Form 10-K Financial Statement

#000158364818000017 Filed on March 15, 2018

View on sec.gov

Income Statement

Concept 2018 Q1 2016 Q4 2016
Revenue $4.152M $2.730M $5.831M
YoY Change 209.16% 27.57% 98.88%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.350M $2.210M $8.890M
YoY Change 9.02% 25.57% 6.21%
% of Gross Profit
Research & Development $7.936M $6.920M $19.70M
YoY Change 48.06% 135.37% 138.93%
% of Gross Profit
Depreciation & Amortization $134.0K $180.0K $400.0K
YoY Change 34.0% 125.0% 29.91%
% of Gross Profit
Operating Expenses $12.29M $9.130M $28.59M
YoY Change 31.44% 94.26% 72.09%
Operating Profit -$8.136M -$22.76M
YoY Change 1.62% 66.35%
Interest Expense $325.0K $0.00 $2.000K
YoY Change -100.0% -101.08%
% of Operating Profit
Other Income/Expense, Net -$903.0K $10.00K $120.0K
YoY Change -7625.0% 0.0% 1000.41%
Pretax Income -$8.714M -$6.400M -$22.64M
YoY Change 9.01% 133.58% 63.39%
Income Tax $0.00 $160.0K $162.0K
% Of Pretax Income
Net Earnings -$8.714M -$6.560M -$22.80M
YoY Change 9.01% 126.21% 62.17%
Net Earnings / Revenue -209.87% -240.29% -391.0%
Basic Earnings Per Share
Diluted Earnings Per Share -$174.0K -$152.3K -$546.6K
COMMON SHARES
Basic Shares Outstanding 53.86M shares 43.06M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q1 2016 Q4 2016
SHORT-TERM ASSETS
Cash & Short-Term Investments $159.6M $29.40M $29.40M
YoY Change 189.13% 0.34% 0.34%
Cash & Equivalents $109.5M $29.36M $29.40M
Short-Term Investments $50.10M
Other Short-Term Assets $3.200M $3.300M $3.300M
YoY Change -8.57% 43.48% 43.48%
Inventory
Prepaid Expenses
Receivables $3.309M $57.00K $100.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $166.1M $32.67M $32.70M
YoY Change 182.66% 3.2% 3.15%
LONG-TERM ASSETS
Property, Plant & Equipment $4.445M $2.264M $2.300M
YoY Change 48.51% 4.68% 4.55%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $2.600M
YoY Change
Other Assets $130.0K $126.0K $100.0K
YoY Change 3.02% -0.62% 0.0%
Total Long-Term Assets $7.158M $2.390M $2.400M
YoY Change 129.48% 4.39% 4.35%
TOTAL ASSETS
Total Short-Term Assets $166.1M $32.67M $32.70M
Total Long-Term Assets $7.158M $2.390M $2.400M
Total Assets $173.2M $35.06M $35.10M
YoY Change 179.98% 3.28% 3.24%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.934M $2.386M $2.400M
YoY Change -41.7% 125.41% 118.18%
Accrued Expenses $6.578M $3.719M $3.700M
YoY Change 122.31% 113.81% 117.65%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $54.76M $8.380M $8.400M
YoY Change 378.5% 199.51% 200.0%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $37.00K $47.00K $1.500M
YoY Change -12.08% 97.05%
Total Long-Term Liabilities $37.00K $47.00K $1.500M
YoY Change -12.08% 97.05%
TOTAL LIABILITIES
Total Short-Term Liabilities $54.76M $8.380M $8.400M
Total Long-Term Liabilities $37.00K $47.00K $1.500M
Total Liabilities $122.5M $9.836M $9.800M
YoY Change 179.53% 248.58% 250.0%
SHAREHOLDERS EQUITY
Retained Earnings -$129.0M -$102.7M
YoY Change 16.6% 28.55%
Common Stock $185.7M $129.4M
YoY Change 42.68% 15.26%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $50.69M $25.23M $25.20M
YoY Change
Total Liabilities & Shareholders Equity $173.2M $35.06M $35.10M
YoY Change 179.98% 3.28% 3.24%

Cashflow Statement

Concept 2018 Q1 2016 Q4 2016
OPERATING ACTIVITIES
Net Income -$8.714M -$6.560M -$22.80M
YoY Change 9.01% 126.21% 62.17%
Depreciation, Depletion And Amortization $134.0K $180.0K $400.0K
YoY Change 34.0% 125.0% 29.91%
Cash From Operating Activities $31.34M -$6.730M -$14.39M
YoY Change 21.61% 169.2% 13.22%
INVESTING ACTIVITIES
Capital Expenditures $414.0K -$260.0K $560.0K
YoY Change 131.28% -25.71% -9.79%
Acquisitions
YoY Change
Other Investing Activities -$7.880M $20.00K $20.00K
YoY Change
Cash From Investing Activities -$8.293M -$240.0K -$560.0K
YoY Change 4507.22% -31.43% -9.68%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $47.21M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $48.16M 0.000 15.22M
YoY Change -100.0% -38.18%
NET CHANGE
Cash From Operating Activities $31.34M -6.730M -14.39M
Cash From Investing Activities -$8.293M -240.0K -560.0K
Cash From Financing Activities $48.16M 0.000 15.22M
Net Change In Cash $71.64M -6.970M 270.0K
YoY Change 179.96% 145.42% -97.61%
FREE CASH FLOW
Cash From Operating Activities $31.34M -$6.730M -$14.39M
Capital Expenditures $414.0K -$260.0K $560.0K
Free Cash Flow $30.93M -$6.470M -$14.95M
YoY Change 20.84% 200.93% 12.15%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017 dei Amendment Flag
AmendmentFlag
false
CY2017 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2017 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2017 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
CY2017 dei Document Period End Date
DocumentPeriodEndDate
2017-12-31
CY2017 dei Document Type
DocumentType
10-K
CY2017 dei Entity Central Index Key
EntityCentralIndexKey
0001583648
CY2018Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
53855371 shares
CY2017 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2017 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Accelerated Filer
CY2017Q2 dei Entity Public Float
EntityPublicFloat
184955062 USD
CY2017 dei Entity Registrant Name
EntityRegistrantName
PIERIS PHARMACEUTICALS, INC.
CY2017 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2017 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2017 dei Trading Symbol
TradingSymbol
PIRS
CY2016Q4 pirs Accrued Research And Development Costs
AccruedResearchAndDevelopmentCosts
1284000 USD
CY2017Q4 pirs Accrued Research And Development Costs
AccruedResearchAndDevelopmentCosts
791000 USD
CY2016Q4 pirs Accrued Tax Audit And Legal Fees
AccruedTaxAuditAndLegalFees
455000 USD
CY2017Q4 pirs Accrued Tax Audit And Legal Fees
AccruedTaxAuditAndLegalFees
424000 USD
CY2015Q3 pirs Area Of Lease Property
AreaOfLeaseProperty
3950 sqft
CY2017Q4 pirs Cash Cash Equivalents And Investments
CashCashEquivalentsAndInvestments
82600000 USD
CY2016Q4 pirs Deferred Tax Assets Accrued Compensation And Other
DeferredTaxAssetsAccruedCompensationAndOther
239000 USD
CY2017Q4 pirs Deferred Tax Assets Accrued Compensation And Other
DeferredTaxAssetsAccruedCompensationAndOther
296000 USD
CY2016 pirs Effective Income Tax Rate Reconciliation Withholding Tax
EffectiveIncomeTaxRateReconciliationWithholdingTax
-0.007
CY2017 pirs Effective Income Tax Rate Reconciliation Withholding Tax
EffectiveIncomeTaxRateReconciliationWithholdingTax
0.000
CY2016 pirs Proceeds From Issuance Of Common And Preferred Stock
ProceedsFromIssuanceOfCommonAndPreferredStock
15221000 USD
CY2017 pirs Proceeds From Issuance Of Common And Preferred Stock
ProceedsFromIssuanceOfCommonAndPreferredStock
0 USD
CY2016 pirs Property And Equipment Included In Accounts Payable
PropertyAndEquipmentIncludedInAccountsPayable
22000 USD
CY2017 pirs Property And Equipment Included In Accounts Payable
PropertyAndEquipmentIncludedInAccountsPayable
114000 USD
CY2017 pirs Tax Cuts And Jobs Act Of2017 Incomplete Accounting Change In Tax Rate Income Tax Expense Benefit Before Valuation Allowance Impact
TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateIncomeTaxExpenseBenefitBeforeValuationAllowanceImpact
-3700000 USD
CY2016Q2 pirs Warrant Exercisable Period
WarrantExercisablePeriod
P5Y
CY2016Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
3719000 USD
CY2017Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
6170000 USD
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2386000 USD
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2452000 USD
CY2016Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
57000 USD
CY2017Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
15546000 USD
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3719000 USD
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6170000 USD
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
624000 USD
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1322000 USD
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2425000 USD
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2879000 USD
CY2016Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1501000 USD
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-4695000 USD
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
129350000 USD
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
136484000 USD
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1905000 USD
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3046000 USD
CY2016 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1905000 USD
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3046000 USD
CY2016Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0 USD
CY2017Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0 USD
CY2016 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8200000 shares
CY2017 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14400000 shares
CY2017Q4 us-gaap Asset Backed Securities At Carrying Value
AssetBackedSecuritiesAtCarryingValue
6384000 USD
CY2016Q4 us-gaap Assets
Assets
35063000 USD
CY2017Q4 us-gaap Assets
Assets
103876000 USD
CY2016Q4 us-gaap Assets Current
AssetsCurrent
32673000 USD
CY2017Q4 us-gaap Assets Current
AssetsCurrent
89790000 USD
CY2017Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
44673000 USD
CY2017Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1000 USD
CY2017Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
820000 USD
CY2017Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
45494000 USD
CY2016 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0 USD
CY2017 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0 USD
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
29350000 USD
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
29356000 USD
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
37878000 USD
CY2016 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
6000 USD
CY2017 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
8522000 USD
CY2017Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
62851000 USD
CY2017Q4 us-gaap Commercial Paper At Carrying Value
CommercialPaperAtCarryingValue
13595000 USD
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0 USD
CY2017 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0 USD
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43058827 shares
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
45017062 shares
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
43058827 shares
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
45017062 shares
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
43000 USD
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
45000 USD
CY2016 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-23028000 USD
CY2017 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-20841000 USD
CY2016 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
162000 USD
CY2017 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
1103000 USD
CY2016 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
162000 USD
CY2017 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
1103000 USD
CY2016 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0 USD
CY2017 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0 USD
CY2016 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0 USD
CY2017 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0 USD
CY2016 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
0 USD
CY2017 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
0 USD
CY2016 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0 USD
CY2017 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0 USD
CY2016Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
1279000 USD
CY2016Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2275000 USD
CY2017Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
37153000 USD
CY2016Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
1409000 USD
CY2017Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
46542000 USD
CY2016 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
0 USD
CY2017 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
0 USD
CY2016Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
0 USD
CY2017Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
1504000 USD
CY2016Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
19817000 USD
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
25250000 USD
CY2016Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 USD
CY2017Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 USD
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
18498000 USD
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
22170000 USD
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
1080000 USD
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
1280000 USD
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
19817000 USD
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
25250000 USD
CY2016 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
32000 USD
CY2016 us-gaap Depreciation
Depreciation
361000 USD
CY2017 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
45000 USD
CY2016 us-gaap Depreciation
Depreciation
400000 USD
CY2017 us-gaap Depreciation
Depreciation
369000 USD
CY2017 us-gaap Depreciation
Depreciation
400000 USD
CY2016 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.55
CY2017 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.40
CY2016 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-267000 USD
CY2017 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
553000 USD
CY2016 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.007
CY2017 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.067
CY2016 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340
CY2016 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.288
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.215
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.222
CY2016 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.029
CY2017 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.012
CY2016 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.023
CY2017 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.000
CY2016 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.009
CY2017 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.018
CY2016 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.009
CY2017 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.024
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1198000 USD
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2325000 USD
CY2017Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
6400000 USD
CY2017 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y3M11D
CY2016 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
0 USD
CY2017 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-156000 USD
CY2016 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8891000 USD
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17584000 USD
CY2017 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 USD
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-8725000 USD
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-13840000 USD
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-22637000 USD
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-16544000 USD
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-13913000 USD
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-2704000 USD
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-22637000 USD
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-16544000 USD
CY2016 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
162000 USD
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1103000 USD
CY2016 us-gaap Income Taxes Paid
IncomeTaxesPaid
162000 USD
CY2017 us-gaap Income Taxes Paid
IncomeTaxesPaid
0 USD
CY2016 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
1360000 USD
CY2017 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-332000 USD
CY2016 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
59000 USD
CY2017 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
14469000 USD
CY2016 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
2063000 USD
CY2017 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
2060000 USD
CY2016 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
3752000 USD
CY2017 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
74378000 USD
CY2016 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1020000 USD
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1900000 USD
CY2016 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
2000 USD
CY2017 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
152000 USD
CY2016 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
500000 USD
CY2017 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
500000 USD
CY2016Q4 us-gaap Liabilities
Liabilities
9836000 USD
CY2017Q4 us-gaap Liabilities
Liabilities
92354000 USD
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
35063000 USD
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
103876000 USD
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8380000 USD
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
45775000 USD
CY2016 us-gaap License And Services Revenue
LicenseAndServicesRevenue
2736000 USD
CY2017 us-gaap License And Services Revenue
LicenseAndServicesRevenue
11285000 USD
CY2016Q4 us-gaap Long Term Investments
LongTermInvestments
0 USD
CY2017Q4 us-gaap Long Term Investments
LongTermInvestments
9922000 USD
CY2017Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
4583000 USD
CY2016 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
15221000 USD
CY2017 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
4090000 USD
CY2016 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-560000 USD
CY2017 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-45875000 USD
CY2016 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-14388000 USD
CY2017 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
49754000 USD
CY2016 us-gaap Net Income Loss
NetIncomeLoss
-22799000 USD
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-17647000 USD
CY2016 us-gaap Operating Expenses
OperatingExpenses
28590000 USD
CY2017 us-gaap Operating Expenses
OperatingExpenses
39869000 USD
CY2016 us-gaap Operating Income Loss
OperatingIncomeLoss
-22759000 USD
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-14594000 USD
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1112000 USD
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
456000 USD
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
34000 USD
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
204000 USD
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
200000 USD
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
218000 USD
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
158000 USD
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1308000 USD
CY2016Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
126000 USD
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
130000 USD
CY2016 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-229000 USD
CY2017 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-2374000 USD
CY2016 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
0 USD
CY2017 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-820000 USD
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
4963 shares
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3260000 USD
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1615000 USD
CY2016 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-229000 USD
CY2017 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-2374000 USD
CY2016Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
47000 USD
CY2017Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
37000 USD
CY2016 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-49000 USD
CY2017 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-293000 USD
CY2016 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
120000 USD
CY2017 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2102000 USD
CY2016 us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
0 USD
CY2017 us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
14000 USD
CY2016 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
0 USD
CY2017 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
43925000 USD
CY2016 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
560000 USD
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1950000 USD
CY2016Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
4963 shares
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
4963 shares
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
4963 shares
CY2016 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 USD
CY2017 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
781000 USD
CY2016 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 USD
CY2017 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
3309000 USD
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4689000 USD
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6913000 USD
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2264000 USD
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4034000 USD
CY2016 us-gaap Research And Development Arrangement Contract To Perform For Others Compensation Earned
ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
1440000 USD
CY2017 us-gaap Research And Development Arrangement Contract To Perform For Others Compensation Earned
ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
1403000 USD
CY2016 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19699000 USD
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22285000 USD
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-102665000 USD
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-120312000 USD
CY2016 us-gaap Revenue Recognition Milestone Method Revenue Recognized
RevenueRecognitionMilestoneMethodRevenueRecognized
1655000 USD
CY2017 us-gaap Revenue Recognition Milestone Method Revenue Recognized
RevenueRecognitionMilestoneMethodRevenueRecognized
12573000 USD
CY2016 us-gaap Revenues
Revenues
5831000 USD
CY2017 us-gaap Revenues
Revenues
25275000 USD
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
1905000 USD
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
3046000 USD
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.760
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2017 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
5500000 USD
CY2016 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
41713000 shares
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.789
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.749
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.751
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0208
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0222
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0113
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0177
CY2016Q4 us-gaap Short Term Investments
ShortTermInvestments
0 USD
CY2017Q4 us-gaap Short Term Investments
ShortTermInvestments
34751000 USD
CY2016Q2 us-gaap Stock Issued During Period Shares Conversion Of Units
StockIssuedDuringPeriodSharesConversionOfUnits
1 shares
CY2017 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
3309000 USD
CY2016 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
15221000 USD
CY2017 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
781000 USD
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
31128000 USD
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
25227000 USD
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
11522000 USD
CY2017Q4 us-gaap Trading Securities
TradingSecurities
34117000 USD
CY2017Q4 us-gaap Us Government Securities At Carrying Value
USGovernmentSecuritiesAtCarryingValue
4172000 USD
CY2016 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
0 USD
CY2017 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
820000 USD
CY2016Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
5655000 USD
CY2017Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
6451000 USD
CY2016Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0 USD
CY2017Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0 USD
CY2017 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
796000 USD
CY2017 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
43931000 shares
CY2017 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Concentration of Credit Risk and Off-Balance Sheet Risk</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has no financial instruments with off&#8209;balance sheet risk such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. Financial instruments that subject Pieris to concentrations of credit risk include cash and cash equivalents, investments, and accounts receivable. The Company&#8217;s cash, cash equivalents, and investments are held in accounts with financial institutions that management believes are creditworthy. The Company&#8217;s investment policy includes guidelines on the quality of the institutions and financial instruments and defines allowable investments that the Company believes minimizes the exposure to concentration of credit risk. These amounts, at times, may exceed federally insured limits. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. Accounts receivable primarily consist of amounts due under strategic partnership and other license agreements with major multi-national pharmaceutical companies for which the Company does not obtain collateral.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"></font></div></div>
CY2017 us-gaap Revenue Recognition Deferred Revenue
RevenueRecognitionDeferredRevenue
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Incremental direct cost</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Incremental direct costs incurred related to the acquisition or origination of a customer contract in a transaction that results in the deferral of revenue are recorded to the statement of operations as incurred.</font></div></div>
CY2017 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of the financial statements in accordance with U.S. GAAP requires management to make estimates, judgments, and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the related disclosures at the date of the financial statements and during the reporting period. Significant estimates are used for, but are not limited to, revenue recognition; deferred tax assets, deferred tax liabilities and valuation allowances; fair value of stock options and various accruals. Management evaluates its estimates on an ongoing basis. Actual results and outcomes could differ materially from management&#8217;s estimates, judgments, and assumptions.</font></div></div>

Files In Submission

Name View Source Status
0001583648-18-000017-index-headers.html Edgar Link pending
0001583648-18-000017-index.html Edgar Link pending
0001583648-18-000017.txt Edgar Link pending
0001583648-18-000017-xbrl.zip Edgar Link pending
exhibit1023.htm Edgar Link pending
exhibit1023001.jpg Edgar Link pending
exhibit1023002.jpg Edgar Link pending
exhibit1023003.jpg Edgar Link pending
exhibit141.htm Edgar Link pending
exhibit141001.jpg Edgar Link pending
exhibit141002.jpg Edgar Link pending
exhibit141003.jpg Edgar Link pending
exhibit141004.jpg Edgar Link pending
exhibit141005.jpg Edgar Link pending
exhibit141006.jpg Edgar Link pending
exhibit141007.jpg Edgar Link pending
exhibit141008.jpg Edgar Link pending
exhibit141009.jpg Edgar Link pending
exhibit141010.jpg Edgar Link pending
exhibit141011.jpg Edgar Link pending
exhibit141012.jpg Edgar Link pending
exhibit141013.jpg Edgar Link pending
exhibit141014.jpg Edgar Link pending
exhibit141015.jpg Edgar Link pending
exhibit141016.jpg Edgar Link pending
exhibit141017.jpg Edgar Link pending
exhibit141018.jpg Edgar Link pending
exhibit141019.jpg Edgar Link pending
exhibit141020.jpg Edgar Link pending
exhibit141021.jpg Edgar Link pending
exhibit211.htm Edgar Link pending
exhibit231.htm Edgar Link pending
exhibit311.htm Edgar Link pending
exhibit312.htm Edgar Link pending
exhibit321.htm Edgar Link pending
exhibit322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g325265g03m91.jpg Edgar Link pending
g325265g27p07.jpg Edgar Link pending
g325265g32v58.jpg Edgar Link pending
g325265g36v11.jpg Edgar Link pending
g325265g37k25.jpg Edgar Link pending
g325265g58h46.jpg Edgar Link pending
g325265g69r07.jpg Edgar Link pending
g325265g72q70.jpg Edgar Link pending
g325265g74z80.jpg Edgar Link pending
g325265g87l78.jpg Edgar Link pending
pierispipeline022618.jpg Edgar Link pending
pirs-20171231.xml Edgar Link completed
pirs-20171231.xsd Edgar Link pending
pirs-20171231_cal.xml Edgar Link unprocessable
pirs-20171231_def.xml Edgar Link unprocessable
pirs-20171231_lab.xml Edgar Link unprocessable
pirs-20171231_pre.xml Edgar Link unprocessable
pirs12-31x201710xk.htm Edgar Link pending
prs060a01.jpg Edgar Link pending
prs080.jpg Edgar Link pending
prs0802.jpg Edgar Link pending
prs0803.jpg Edgar Link pending
prs343.jpg Edgar Link pending
prs3432.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending